BRPI0913580B8 - compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos - Google Patents
compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostosInfo
- Publication number
- BRPI0913580B8 BRPI0913580B8 BRPI0913580A BRPI0913580A BRPI0913580B8 BR PI0913580 B8 BRPI0913580 B8 BR PI0913580B8 BR PI0913580 A BRPI0913580 A BR PI0913580A BR PI0913580 A BRPI0913580 A BR PI0913580A BR PI0913580 B8 BRPI0913580 B8 BR PI0913580B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical composition
- kinase inhibitors
- pyrrolopyridine
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000005255 pyrrolopyridines Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101150050673 CHK1 gene Proteins 0.000 abstract 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5292608P | 2008-05-13 | 2008-05-13 | |
| US61/052,926 | 2008-05-13 | ||
| PCT/US2009/043691 WO2009140320A1 (en) | 2008-05-13 | 2009-05-13 | Pyrrolopyridines as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0913580A2 BRPI0913580A2 (pt) | 2015-10-20 |
| BRPI0913580B1 BRPI0913580B1 (pt) | 2020-03-10 |
| BRPI0913580B8 true BRPI0913580B8 (pt) | 2021-05-25 |
Family
ID=40810786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913580A BRPI0913580B8 (pt) | 2008-05-13 | 2009-05-13 | compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8178131B2 (enExample) |
| EP (2) | EP2990407B1 (enExample) |
| JP (2) | JP5703212B2 (enExample) |
| KR (2) | KR101643426B1 (enExample) |
| CN (3) | CN102089307B (enExample) |
| AR (1) | AR071717A1 (enExample) |
| AU (1) | AU2009246402B2 (enExample) |
| BR (1) | BRPI0913580B8 (enExample) |
| CA (1) | CA2724262C (enExample) |
| CL (1) | CL2009001152A1 (enExample) |
| CO (1) | CO6321244A2 (enExample) |
| CR (1) | CR11803A (enExample) |
| CY (1) | CY1116692T1 (enExample) |
| DK (1) | DK2307409T3 (enExample) |
| ES (1) | ES2552643T3 (enExample) |
| HK (1) | HK1219950A1 (enExample) |
| HR (1) | HRP20151018T1 (enExample) |
| HU (1) | HUE026160T2 (enExample) |
| IL (1) | IL209258A (enExample) |
| MX (1) | MX2010012449A (enExample) |
| NZ (1) | NZ589318A (enExample) |
| PH (1) | PH12013501779B1 (enExample) |
| PL (1) | PL2307409T3 (enExample) |
| PT (1) | PT2307409E (enExample) |
| RS (1) | RS54358B1 (enExample) |
| RU (1) | RU2517194C2 (enExample) |
| SI (1) | SI2307409T1 (enExample) |
| TW (2) | TWI458727B (enExample) |
| UA (1) | UA111933C2 (enExample) |
| WO (1) | WO2009140320A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| EP2242757B1 (en) | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| JP2009256298A (ja) * | 2008-03-26 | 2009-11-05 | Sumitomo Chemical Co Ltd | ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体 |
| CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| KR101676062B1 (ko) * | 2009-04-11 | 2016-11-14 | 어레이 바이오파마 인크. | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011029043A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| BR112013003864B1 (pt) | 2010-08-20 | 2021-08-31 | Hutchison Medipharma Limited | Compostos de pirrolpirimidina, composição e uso dos mesmos |
| CN108721284A (zh) | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
| MX339899B (es) | 2011-02-25 | 2016-06-16 | Array Biopharma Inc | Compuestos de triazolopiridina como inhibidores de pim cinasa. |
| JP2014516941A (ja) | 2011-04-29 | 2014-07-17 | アムジェン インコーポレイテッド | Ｐｉｍ阻害剤としての二環式ピリダジン化合物 |
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| RU2635359C2 (ru) * | 2012-04-23 | 2017-11-13 | Дженентек Инк. | Промежуточные химические соединения и способы получения соединений |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
| CA2921956C (en) * | 2013-08-22 | 2021-10-19 | Genentech, Inc. | Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine |
| RU2675814C2 (ru) | 2013-09-25 | 2018-12-25 | Вертекс Фармасьютикалз Инкорпорейтед | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| MA41599A (fr) * | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
| WO2017003090A1 (ko) | 2015-06-30 | 2017-01-05 | 서울바이오시스 주식회사 | Uv led가 적용된 포충기 |
| TW202510883A (zh) * | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| TWI873098B (zh) * | 2018-07-03 | 2025-02-21 | 瑞士商諾華製藥公司 | 用於治療與sting活性相關之病症的化合物及組合物 |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| CN109053526A (zh) * | 2018-08-13 | 2018-12-21 | 南通大学 | 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法 |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| WO2022015975A1 (en) | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP2024502474A (ja) | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物 |
| AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| CN119798252A (zh) * | 2023-10-09 | 2025-04-11 | 中国石油化工股份有限公司 | 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法 |
| TW202617721A (zh) * | 2024-06-14 | 2026-05-01 | 美商騰維療法股份有限公司 | 化合物、組成物及方法 |
| TW202604487A (zh) * | 2024-06-18 | 2026-02-01 | 大陸商南京正大天晴製藥有限公司 | 五員并六員雜環化合物及用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE217309T1 (de) | 1993-10-14 | 2002-05-15 | Abbott Lab | Verbindungen des chinolizinon-typs |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US6797825B2 (en) * | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| AU2004220176A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| US7514448B2 (en) * | 2004-04-02 | 2009-04-07 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| TWI380816B (zh) * | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
| JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| BRPI0608659A2 (pt) | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| AU2006285915B2 (en) * | 2005-08-30 | 2011-02-24 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| PE20070543A1 (es) | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
| US20070082900A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
| DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
| WO2007125321A2 (en) * | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| US20090253718A1 (en) | 2006-04-25 | 2009-10-08 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| WO2009061781A1 (en) | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| WO2009089352A1 (en) * | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| EP2242757B1 (en) * | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US20140221370A1 (en) | 2010-07-09 | 2014-08-07 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| CN108721284A (zh) | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
-
2009
- 2009-05-12 CL CL2009001152A patent/CL2009001152A1/es unknown
- 2009-05-12 AR ARP090101708A patent/AR071717A1/es active IP Right Grant
- 2009-05-13 ES ES09747404.3T patent/ES2552643T3/es active Active
- 2009-05-13 TW TW098115906A patent/TWI458727B/zh not_active IP Right Cessation
- 2009-05-13 TW TW103133772A patent/TWI554512B/zh not_active IP Right Cessation
- 2009-05-13 JP JP2011509628A patent/JP5703212B2/ja not_active Expired - Fee Related
- 2009-05-13 PT PT97474043T patent/PT2307409E/pt unknown
- 2009-05-13 WO PCT/US2009/043691 patent/WO2009140320A1/en not_active Ceased
- 2009-05-13 KR KR1020107027941A patent/KR101643426B1/ko not_active Expired - Fee Related
- 2009-05-13 SI SI200931284T patent/SI2307409T1/sl unknown
- 2009-05-13 DK DK09747404.3T patent/DK2307409T3/en active
- 2009-05-13 EP EP15175131.0A patent/EP2990407B1/en active Active
- 2009-05-13 RS RS20150711A patent/RS54358B1/sr unknown
- 2009-05-13 CN CN200980127299.4A patent/CN102089307B/zh not_active Expired - Fee Related
- 2009-05-13 KR KR1020147015705A patent/KR101657856B1/ko not_active Expired - Fee Related
- 2009-05-13 PL PL09747404T patent/PL2307409T3/pl unknown
- 2009-05-13 HU HUE09747404A patent/HUE026160T2/en unknown
- 2009-05-13 CN CN201910068067.1A patent/CN109942575A/zh active Pending
- 2009-05-13 US US12/992,468 patent/US8178131B2/en active Active
- 2009-05-13 CA CA2724262A patent/CA2724262C/en active Active
- 2009-05-13 BR BRPI0913580A patent/BRPI0913580B8/pt not_active IP Right Cessation
- 2009-05-13 RU RU2010150786/04A patent/RU2517194C2/ru active
- 2009-05-13 AU AU2009246402A patent/AU2009246402B2/en not_active Ceased
- 2009-05-13 UA UAA201015012A patent/UA111933C2/uk unknown
- 2009-05-13 HR HRP20151018TT patent/HRP20151018T1/hr unknown
- 2009-05-13 EP EP09747404.3A patent/EP2307409B1/en active Active
- 2009-05-13 MX MX2010012449A patent/MX2010012449A/es active IP Right Grant
- 2009-05-13 NZ NZ589318A patent/NZ589318A/en not_active IP Right Cessation
- 2009-05-13 CN CN201510289964.7A patent/CN104926810B/zh not_active Expired - Fee Related
-
2010
- 2010-11-11 IL IL209258A patent/IL209258A/en active IP Right Grant
- 2010-11-19 CR CR11803A patent/CR11803A/es unknown
- 2010-11-30 CO CO10150963A patent/CO6321244A2/es active IP Right Grant
-
2012
- 2012-03-20 US US13/425,186 patent/US8545897B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 US US13/974,895 patent/US8758830B2/en not_active Expired - Fee Related
- 2013-08-28 PH PH12013501779A patent/PH12013501779B1/en unknown
-
2014
- 2014-05-06 US US14/271,129 patent/US8981085B2/en active Active
-
2015
- 2015-01-07 US US14/591,691 patent/US9365568B2/en active Active
- 2015-02-23 JP JP2015032474A patent/JP2015098482A/ja not_active Withdrawn
- 2015-09-16 CY CY20151100812T patent/CY1116692T1/el unknown
-
2016
- 2016-01-05 US US14/988,521 patent/US9969727B2/en not_active Expired - Fee Related
- 2016-07-08 HK HK16107983.6A patent/HK1219950A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
| UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
| UA111756C2 (uk) | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона | |
| BRPI0713923B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos | |
| BRPI0812504B8 (pt) | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero | |
| BR112012027062A2 (pt) | composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica | |
| CL2011000124A1 (es) | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
| BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
| BR112012012815A2 (pt) | composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica | |
| BR112014021634A8 (pt) | inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula | |
| BR112016015235A2 (pt) | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| BR112013028430A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto | |
| BR112013014914B8 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
| BR112012019635A2 (pt) | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| CL2009001151A1 (es) | Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos. | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |